Atopic Dermatitis (AD) is the second most common chronic inflammatory (coming for you acne!) which unapologetically imparts a tremendous burden on society as a whole. But what if you could jump in the DeLorean with Doc Brown, rev up to 88 miles per hour, and go back in time to stop it in the first place…would you? Um, of course you would. Well time travel isn’t a thing yet, so we need to do the next best thing and try to prevent disease in high-risk individuals from day one – literally. Does this work, you say? We get it, the flip-flopping evidence can make anyone confused but have no fear as help is here. JDD Podcast host Dr. Adam Friedman is joined by clarifying captains of industry Dr. Candrice Heath and Dr. Jonathan Hourihane to review best practices to identify AD high risk infants, what to do about it, and what the evidence tells us. STOP AD… both our goal and the name of the innovative study about which you need to be “poducated.”
Atopic dermatitis does not discriminate. The second most common inflammatory skin disease (coming for you, acne vulgaris) can be appreciated across all demographics which contributes to the insane heterogeneity about which we are commonly taught. Unique considerations and approaches must be employed to ensure a personalized approach. Join Dr. Katrina Abuabara, Associate Professor of Epidemiology and Dermatology at UCSF, as she reviews her approach to caring for the geriatric AD population and their caregivers with JDD Podcast host Dr. Adam Friedman. This topic never gets old!
This podcast series is supported by Pfizer.
Cutting the cord for residency training can feel like losing one’s Netflix account, distanced from the epicenter of cultural or dermatologic life. How to stay engaged, involved, or even keep your finger on the rapid pulse of innovation or development you ask? It’s as simple as sending an email. JDD Podcast host Dr. Adam Friedman takes a deep dive with National Eczema Association (NEA) Vice President of Scientific and Clinical Affairs Wendy Smith-Begolka on all paths to engagement. Education, research, community advocacy…it’s all there and a 5 gm sample tube throw away (meaning real close). Tune in to learn how to continue the cutaneous connection.
This podcast series is supported by Pfizer.
Hall of famers Dr.s Amy Paller and Jonathan Silverberg join host Dr. Adam Friedman to review current moderate to severe AD treatment approaches and use of systemic therapies, discuss advancement on AD clinical management with use of novel target therapy, and share clinical experience with the use of biologics treatment. As we have all been thrown a curve ball in life, faculty address the growing concerns surrounding dermatology-related immunosuppressant therapy during the pandemic and how to discuss this issue with patients. Slide into home with a peak at the future therapies landscape in clinical development.
The Ps of Lichen Planus got nothing on this alliteration filled podcast that was purposefully positioned to perfect your practice prowess to punish the pruritus and picking of atopic dermatitis. Join host Dr. Adam Friedman in part four of five of this Atopic Dermatitis dedicated series as he parties with and picks the brains of dermatology powerhouses Dr.s April Armstrong and Lawrence Eichenfield on pursuing a practical and powerful process to partner with patients of all ages and partake in a long standing management strategy.
Atopic Dermatitis (AD). This exceedingly common chronic inflammatory disease is unavoidable in practice, and to best manage/partner with the millions of patients out there, it is on us to view/appreciate this condition beyond the practitioner lens.
Host Dr. Adam Friedman is joined by Dr. Lindsey Finklea, a practicing dermatologist and parent/caregiver of a child with severe AD, and Dr. Peter Lio, podcast veteran and AD focused Derm extraordinaire, to discuss the issues affecting patient-family/patient-caregiver interactions and offer clinical pearls for effective management strategies to best assist the needs of parents, families and caregivers for patients with the AD.
Dr. Adam Friedman is joined by the dynamic dermatitis duo Dr. Anna De Benedetto, Associate Professor of Dermatology at the University of Florida, and Dr. Eric Simpson, Professor of Dermatology at the School of Medicine at Oregon Health & Science University, to dissect established and emerging pathophysiologic details of this dastardly dermatitis.
We are finally getting what we asked for: Pharma is ponying up for head to head studies to provide us with meaningful data to help make better clinical decisions. However, these valuable projects are often with systemic agents, such as biologics, leaving topical treatments in the dust. To address this, Dr. Lawrence Eichenfield, Professor of Dermatology and Pediatrics, UCSD, and colleagues sought to make the most out of the data we do have on the litany of topical options for atopic dermatitis and provide efficacy and safety guidance (A for effort!). Tune in to hear what this dream team concocted about creams. Hear how an expert approaches new atopic dermatitis patients. Don’t miss out – this is all very topical.
Back by popular demand, Dr. Steven Feldman, Professor of Dermatology, Pathology and Public Health joins host Dr. Adam Friedman from GW School of Medicine to review his recent database dive entitled “Trends in Atopic Dermatitis Management: Comparison of 1990-1997 to 2003-2012.” What new trends, both good and bad, have emerged? What can we expect and hope for the future of AD care? What tricks of the trade do these two employ when utilizing systemic immunosuppressants? Itching for answers? Make sure to tune in…
In this edition of the JDD Podcast, Ask the Investigator, host Dr. Adam Friedman digs deep with UCSF Assistant Professor of Dermatology Dr. Tina Bhutani to powerlift the most up to date safety data on Class 1 superpotent topical steroids from her study entitled “Update on the Systemic Risks of Superpotent Topical Steroids.” Is steroid phobia valid, or does proper use of steroids properly protect from the adverse event boogeyman. Hear from the expert how to effectively use topical steroids while limiting local and systemic side effects, and how to get your patients on board, especially those nay sayers. Do not miss this clinically relevant and im-POTENT podcast ( nailed it!).
In this special edition of the JDD podcast, with consideration from La Roche-Posay, host Dr. Adam Friedman is joined by Acne guru Dr. Hilary Baldwin, Director of the Acne Research Center and Associate Professor of Dermatology at SUNY Downstate, to review the cutting edge of cutaneous microbiome research and translational applications. Yes you are covered in bacteria – accept it, own it, and love it. Learn how harmony between the >500 species on our skin keep our barrier and cutaneous immunity in check, and conversely, how dysbiosis can facilitate a broad range of cutaneous pathology. This special edition is not to be missed!
We are finally getting what we asked for: Pharma is ponying up for head to head studies to provide us with meaningful data to help make better clinical decisions. However, these valuable projects are often with systemic agents, such as biologics, leaving topical treatments in the dust. To address this, Dr. Lawrence Eichenfield, Professor of Dermatology and Pediatrics, UCSD, and colleagues sought to make the most out of the data we do have on the litany of topical options for atopic dermatitis and provide efficacy and safety guidance (A for effort!). Tune in to hear what this dream team concocted about creams. Hear how an expert approaches new atopic dermatitis patients. Don’t miss out – this is all very topical.
Back by popular demand, Dr. Steven Feldman, Professor of Dermatology, Pathology and Public Health joins host Dr. Adam Friedman from GW School of Medicine to review his recent database dive entitled “Trends in Atopic Dermatitis Management: Comparison of 1990-1997 to 2003-2012.” What new trends, both good and bad, have emerged? What can we expect and hope for the future of AD care? What tricks of the trade do these two employ when utilizing systemic immunosuppressants? Itching for answers? Make sure to tune in…
In this edition of the JDD Podcast, Ask the Investigator, host Dr. Adam Friedman digs deep with UCSF Assistant Professor of Dermatology Dr. Tina Bhutani to powerlift the most up to date safety data on Class 1 superpotent topical steroids from her study entitled “Update on the Systemic Risks of Superpotent Topical Steroids.” Is steroid phobia valid, or does proper use of steroids properly protect from the adverse event boogeyman. Hear from the expert how to effectively use topical steroids while limiting local and systemic side effects, and how to get your patients on board, especially those nay sayers. Do not miss this clinically relevant and im-POTENT podcast ( nailed it!).
In this special edition of the JDD podcast, with consideration from La Roche-Posay, host Dr. Adam Friedman is joined by Acne guru Dr. Hilary Baldwin, Director of the Acne Research Center and Associate Professor of Dermatology at SUNY Downstate, to review the cutting edge of cutaneous microbiome research and translational applications. Yes you are covered in bacteria – accept it, own it, and love it. Learn how harmony between the >500 species on our skin keep our barrier and cutaneous immunity in check, and conversely, how dysbiosis can facilitate a broad range of cutaneous pathology. This special edition is not to be missed!
Dr. Jon Zippin, Assistant Attending Dermatologist and Assistant Professor of Dermatology at Weill Medical College of Cornell, elucidates the complexity of cAMP biology and the translational impact of PDE4 inhibition as it relates to chronic inflammatory skin diseases. Tune in to learn why targeting this pathway is clinically meaningful but also where more work is needed to improve outcomes.
Dr. Amy Paller, Walter J. Hamlin Professor and Chair of Dermatology & Professor of Pediatrics at Northwestern University Feinberg School of Medicine in Chicago, Illinois, delivers a presentation discussing the cause and treatment of pediatric Atopic Dematitis, including co-morbidities, epidermal barrier impairment, and compliance issues.
Dr. Gil Yosipovitch, Professor of Dermatology at University of Miami Miller School of Medicine, provides residents and physicians access to the latest bench research and practical pearls from a master in pruritus that will help them offer the highest quality evidence-based dermatological care.
© 2023 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
